- Home
- ENTX vs CFBK Comparison
ENTX vs CFBK Comparison
Compare ENTX & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTX | CFBK |
|---|---|---|
| Founded | 2010 | 1892 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 167.9M |
| IPO Year | 2018 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ENTX | CFBK |
|---|---|---|
| Price | $1.71 | $26.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $29.00 |
| AVG Volume (30 Days) | ★ 219.0K | 73.9K |
| Earning Date | 11-14-2025 | 02-11-2026 |
| Dividend Yield | N/A | ★ 1.41% |
| EPS Growth | N/A | ★ 21.79 |
| EPS | N/A | ★ 2.49 |
| Revenue | $124,000.00 | ★ $50,724,000.00 |
| Revenue This Year | N/A | $39.98 |
| Revenue Next Year | N/A | $10.47 |
| P/E Ratio | ★ N/A | $10.24 |
| Revenue Growth | ★ 25.25 | 14.25 |
| 52 Week Low | $1.50 | $19.23 |
| 52 Week High | $3.22 | $27.46 |
Technical Indicators
Market Signals| Indicator | ENTX | CFBK |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 67.91 |
| Support Level | $1.53 | $24.32 |
| Resistance Level | $1.99 | $26.46 |
| Average True Range (ATR) | 0.19 | 0.78 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 32.73 | 74.09 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.